As go drug sales (and prices), so go the fortunes of drug distributors like Pennsylvania-based AmerisourceBergen, which acts as a middleman, delivering medicines from manufacturers to pharmacies and hospitals. AmerisourceBergen’s revenues climbed 9.7% in 2018 thanks to overall market growth and brisk sales of expensive cancer drugs. The company’s acquisition of wholesaler H.D. Smith—completed in January of 2018—and the performance of its joint venture with Profarma in Brazil also boosted revenues, as did AmerisourceBergen’s veterinary medicine business. The company is facing issues involving its drug compounding subsidiary PharMEDium and, like its competitors, AmerisourceBergen is under scrutiny for its alleged role in the nation’s opioid crisis.
Company Info
| CEO | Steven H. Collis |
| CEO Title | Chairman, President & Chief Executive Officer |
| Sector | Health Care |
| Industry | Wholesalers: Health Care |
| HQ Location | Chesterbrook, Pa. |
| Website | www.amerisourcebergen.com |
| Years on Fortune 500 List | 25 |
| Employees | 20,500 |
Key Financials (Last Fiscal Year)
| Revenues ($M) | $167,939.6 |
| Profits ($M) | $1,658.4 |
| Assets ($M) | $37,669.8 |
| Total Stockholder Equity ($M) | $2,932.8 |
Profit Ratios
| Profit as % of Revenues | 1.0% |
| Profits as % of Assets | 4.4% |
| Profits as % of Stockholder Equity | 56.5% |
Earnings Per Share (Last Fiscal Year)
| Earnings Per Share ($) | 8 |
| EPS % Change (from 2017) | 359.1% |
| EPS % Change (5 year annual rate) | 32.6% |
| EPS % Change (10 year annual rate) | 25.6% |
Total Return
| Total Return to Investors (2018) | -17.6% |
| Total Return to Investors (5 year, annualized) | 2.7% |
| Total Return to Investors (10 year, annualized) | 17.0% |